*Clostridium difficile* associated disease
==========================================

*Clostridium difficile* was first described in 1935 by Ivan Hall and Elizabeth O\'Toole (Hall and O\'Toole, [@B38]). The researchers discovered the bacteria while investigating the bacterial colonization of the intestinal tracts of normal infants during the first 10 days following birth. Hall and O\'Toole found that *C. difficile* was toxic toward animals and produced secreted toxic factor(s). Nevertheless, the bacteria had been isolated from normal infants, and there was no indication that the presence of the bacteria had any deleterious effects on the newborns. Thus, for the next four decades *C. difficile* remained a little known bacterium that was considered a part of the normal intestinal flora of infants.

*C. difficile*\'s rise from obscurity began in the 1970s when it was found to be the primary cause of pseudomembranous colitis (PMC). PMC is a severe condition characterized by inflammation of the colon with the formation of plaques, or pseudomembranes, composed of fibrin, mucin, necrotic epithelial cells, and neutrophils. (Lyerly et al., [@B61]; Kelly et al., [@B52]). PMC had been described as early as 1893, but the causative agent was undefined for decades (Finney, [@B26]). Following the development and use of broad-spectrum antibiotics, the number of PMC cases increased dramatically (Lyerly et al., [@B61]). An especially large number of reported cases occurred in the 1970s following introduction of clindamycin (Cohen et al., [@B20]; Kabins and Spira, [@B49]). With this rise in incidence, the search for the cause of PMC intensified, and by the late 1970s there was strong evidence from a number of groups that *C. difficile* was the causative agent (Lyerly et al., [@B61]). Moreover, the toxic secreted components that Hall and O\'Toole noted in filtrates from *C. difficile* cultures were implicated in causing PMC. The toxic components were identified as two proteins, toxin A (TcdA) and toxin B (TcdB).

Although the pathogenicity of *C. difficile* toward humans was first discovered in relation to its ability to cause PMC, it is now known that the manifestations of *C. difficile* infection can range from asymptomatic carriage, to mild diarrhea, to life-threatening conditions such as PMC and toxic megacolon. Collectively, the manifestations of disease caused by *C. difficile* are referred to as *C. difficile* associated disease (CDAD). Sohn et al. have estimated that there are 7 CDAD case patients per 1,000 admissions in acute care hospitals (Sohn et al., [@B108]). It should be noted, however, that *C. difficile* burden varies dramatically by geographic region, between institutions, and even between wards of the same hospital (Lyerly et al., [@B61]; Bartlett, [@B12]; Sohn et al., [@B108]; McDonald et al., [@B67]). Total costs of *C. difficile* to the US health care system are thought to exceed \$3 billion per year (Kyne et al., [@B57]; Brazier, [@B15]).

Between the late 1990s and mid 2000s there was a dramatic increase in the number of cases of CDAD. Rates of CDAD more than doubled in many localities (Kelly and LaMont, [@B51]). According to death certificate data, *C. difficile* related deaths in the US rose from 5.7 deaths per million in the population in 1999 to 23.7 in 2004 (Redelings et al., [@B92]). This vast upsurge in CDAD has been primarily attributed to the emergence of more virulent strains categorized as North American pulsotype 1/PCR-ribotype 027 (NAP1/027). NAP1/027 strains have been reported to have higher production of TcdA and TcdB (Warny et al., [@B123]), a more cytopathic form of TcdB (Stabler et al., [@B109]; Lanis et al., [@B59]), production of binary toxin (McDonald et al., [@B68]), higher rates of sporulation (Merrigan et al., [@B70]; Akerlund et al., [@B1]), and increased antibiotic resistance (McDonald et al., [@B68]).

Virulence factors of C. difficile
=================================

Several factors have been implicated in the virulence of *C. difficile* including adhesins (Waligora et al., [@B121]), extracellular enzymes (Savariau-Lacomme et al., [@B99]), fimbrae (Borriello et al., [@B14]), flagella (Delmee et al., [@B21]; Stabler et al., [@B110]), capsule (Borriello et al., [@B14]), and a paracrystalline S-layer (Karjalainen et al., [@B50]; Sebaihia et al., [@B101]). In addition, *C. difficile* produces three secreted protein toxins: TcdA, TcdB, and the binary toxin CDTab. CDTab is an actin-specific ADP-ribosyltransferase that is homologous to iota toxin from *C. perfringens* (Popoff et al., [@B81]; Perelle et al., [@B79]). Many pathogenic strains do not produce CDTab (Rupnik et al., [@B96]), and the role of binary toxin in pathogenesis is unclear (Perelle et al., [@B79]; Barbut et al., [@B9]; Geric et al., [@B32]).

TcdA and TcdB are 308 and 270 kDa proteins, respectively, with 49% identity and 63% similarity. They belong to a larger family of large clostridial toxins (LCTs) which includes lethal and hemorrhagic toxins from *C. sordellii* (TcsL and TcsH), α-toxin from *C. novyi* (Tcnα), and large cytotoxin from *C. perfringens* (TpeL) (Table [1](#T1){ref-type="table"}). LCTs are homologous toxins that inactivate host Rho and Ras family guanosine triphosphatases (GTPase) by glucosylation. The Rho and Ras family GTPases are master regulators of a number of vital cellular processes including cycle progression, cell-cell adhesion, cytokinesis, secretion, and maintenance of the cytoskeleton (Bishop and Hall, [@B13]; Jank et al., [@B45]).

###### 

**Large clostridial toxins**.

  **Toxin**                                **Species**     **Mol. weight**                            **Lethal activity[^1^](#TN1){ref-type="table-fn"}**   **Targets**
  ---------------------------------------- --------------- ------------------------------------------ ----------------------------------------------------- ----------------------
  TcdA                                     *difficile*     308 kDa                                    50 ng                                                 Rho, Rac, Cdc42, Rap
  TcdB                                     *difficile*     270 kDa                                    50 ng                                                 Rho, Rac, Cdc42
  TcdB-F[^2^](#TN2){ref-type="table-fn"}   *difficile*     270 kDa                                    50 ng                                                 Rac, Ras, Ral, Rap
  TcsH                                     *sordellii*     ∼300 kDa[^3^](#TN3){ref-type="table-fn"}   75 ng                                                 Rho, Rac, Cdc42
  TcsL                                     *sordellii*     270 kDa                                    5 ng                                                  Rac, Ras, Ral, Rap
  Tcnα                                     *novyi*         250 kDa                                    5--10 ng                                              Rho, Rac, Cdc42
  TpeL                                     *perfringens*   191 kDa                                    16 μg                                                 Rac, Ras, Ral, Rap

Amounts listed are for one mouse lethal dose and were obtained by intraperitoneal injection (Ball et al., [@B8]; Amimoto et al., [@B6]).

TcdB-F is a variant TcdB produced by the TcdA^−^TcdB^+^ strain 1470 (Chaves-Olarte et al., [@B16]).

The amino acid sequence for TcsH is unknown. The estimated molecular weight is based on SDS-PAGE (Martinez and Wilkins, [@B65]).

Roles of TcdA and TcdB *in vivo*
================================

Effects of the toxins on cells
------------------------------

The most obvious change in cells treated with TcdA or TcdB is the loss of cytoskeletal structure. Both toxins induce rounding in a wide range of cell types. Although TcdA and TcdB have the same general mechanism of action, they have several phenotypic differences. In the capacity to round cells, TcdB is 100--10,000 times more potent than TcdA in many cell types (Donta et al., [@B22]; Tucker et al., [@B114]; Aktories, [@B2]; Chaves-Olarte et al., [@B17]).

TcdA and TcdB also cause cells to die. Cell death and cell-rounding are distinct events in intoxication (Qa\'Dan et al., [@B89]). To distinguish between the two events, cell-rounding and cell death are sometimes referred to as the cytopathic effect and cytotoxic effect, respectively. TcdA and TcdB have been reported to cause death through a number of different mechanisms including p53-dependent and p53-independent apoptosis, caspase-dependent and caspase-independent apoptosis, as well as necrosis (Warny and Kelly, [@B122]; Hippenstiel et al., [@B40]; Qa\'Dan et al., [@B89]; Kim et al., [@B53]; Matarrese et al., [@B66]; Nottrott et al., [@B75]).

TcdA and TcdB have a number of effects on cells that do not necessarily result in rounding or death, yet may contribute to pathogenesis. Inactivation of Rho GTPases by TcdA and TcdB results in the disruption of cell-cell junctions, which may contribute to the increased epithelial permeability and lumenal fluid accumulation associated with CDAD (Feltis et al., [@B25]; Johal et al., [@B47]). Both toxins also induce the secretion of cytokines in epithelial and immune cells. These include tumor necrosis factor, IL-1, IL-6, and IL-8 (Savidge et al., [@B100]). IL-8, in particular, is thought to play a pivotal role in *C. difficile* pathogenesis. IL-8 is involved in the recruitment and activation of neutrophils, which are present in high amounts at sites of *C. difficile* associated inflammation. A polymorphism in the IL-8 gene has been associated with susceptibility to recurrent CDAD (Jiang et al., [@B46]).

Effects of the toxins in animals
--------------------------------

The activities of purified TcdA and TcdB have been investigated in a number of animal models including mice, rats, rabbits, and hamsters. Although the manifestations of disease vary in the different animals, in these models TcdA induces fluid accumulation and inflammation within the intestinal tract, whereas TcdB causes minimal or no intestinal pathology (Lyerly et al., [@B62], [@B63]; Mitchell et al., [@B72]). In the rabbit ligated ileal loops, for example, TcdA induces fluid accumulation with comparable activity to cholera toxin (Lyerly et al., [@B62]). Unlike cholera toxin, the toxin also causes extensive tissue damage and the accumulated fluid is hemorrhagic (Lyerly et al., [@B62], [@B61]). TcdB has no effect in this assay. Likewise, when TcdA and TcdB are given to mice and hamsters intragastrically, TcdA causes intestinal hemorrhage, diarrhea, and death, but TcdB has no effect (Lyerly et al., [@B63]). TcdB, is however, a potent toxin toward these animals when administered by other routes. When given by intraperitoneal injection, TcdA and TcdB are both lethal toxins with similar potencies (Table [1](#T1){ref-type="table"}) (Ball et al., [@B8]).

Based on these early studies, TcdA was referred to as the enterotoxin, and TcdB, because of its ∼1000-fold higher cytopathic potency toward cultured cells, was referred to as the cytotoxin. It was proposed that TcdA induced the initial damage in the colon where TcdB alone was relatively inert. After TcdA had disrupted the intestinal epithelium, TcdB might then access and act on other tissues (Lyerly et al., [@B61]). This model implicated TcdA as the key virulence factor in disease and TcdB as, perhaps, an accessory virulence factor. In support of this model, Lyerly et al. showed that if TcdB is given to hamsters with damaged intestines or together with sublethal doses of TcdA the animals die. Furthermore, a humoral immune response against TcdA correlates with protection from disease both in humans and in animal models (Warny et al., [@B124]; Kyne et al., [@B58]; Giannasca and Warny, [@B33]; Babcock et al., [@B7]).

More recently, a number of pieces of evidence have shown TcdB has a much more important role in disease than previously appreciated. Since the 1990s, a number of pathogenic strains have been identified that produce TcdB, but not TcdA. These TcdA^−^TcdB^+^ strains cause the same range of symptoms as TcdA^+^TcdB^+^ strains in humans, and are pathogenic in animal models (Sambol et al., [@B98]). Thus TcdA is not essential for pathogenesis. To date, no pathogenic TcdA^+^TcdB^−^ clinical isolates have been identified. In addition, there have been reports that while TcdB may not be enterotoxic in animal models, it is toxic toward human colonic tissues. Riegler et al. tested the effects of TcdA and TcdB on human colonic explants and found that TcdB was ∼10 times more potent than TcdA at disrupting the integrity of the membrane (Riegler et al., [@B95]). Savidge et al. have demonstrated the toxicity of TcdB in a chimeric mouse model of disease where a human fetal intestinal xenograft is transplanted into an immunodeficient mouse (Savidge et al., [@B100]). When challenged with either TcdA or TcdB, the human xenografts exhibited intestinal epithelial cell damage with marked necrosis, increased mucosal permeability, and acute mucosal inflammation.

Elucidating the roles of TcdA and TcdB in pathogenesis has been slow, partially due to the lack of genetic tools for the manipulation of *C. difficile* (O\'Connor et al., [@B76]). In 2009, Lyras et al. reported results from animal infections conducted with *tcdA* and *tcdB* mutants (Lyras et al., [@B64]). Clindamycin-treated hamsters were challenged with isogenic strains lacking either toxin. Surprisingly, knocking out TcdA seemed to have no effect on the virulence of the strain. Strains lacking TcdB, however, were avirulent. Death of the hamster was the only reported phenotype, so it is not clear if the TcdA^+^TcdB^−^ strains had subtler pathological effects. In similar experiments carried out by Kuehne et al., TcdA and TcdB deficient mutants were both shown to have pathologic effects in hamsters (Kuehne et al., [@B56]). Efforts to further evaluate the roles of toxin in the context of mouse infection models are on-going (Chen et al., [@B18]).

Although TcdA and TcdB have long been accepted as the primary virulence factors of *C. difficile*, it is clear that the two toxins have distinctive properties both in animals and on cells. In addition, several isoforms of TcdB have been noted. TcdB from the NAP1/027 strain R20291 is \>1000-fold more cytopathic than TcdB from the prototypical 630 strain on a number of cell lines (Stabler et al., [@B111]). TcdA^−^TcdB^+^ strains (e.g., 1470 and 8864) produce variant forms of TcdB that have altered substrate specificity. Understanding the molecular roles of TcdA, TcdB, and variant toxins in pathogenesis is important for the development of therapeutic strategies aimed at disrupting the action of these toxins.

TcdA and TcdB structure and mechanism of action
===============================================

TcdA and TcdB are homologous AB toxins. They can be divided into two components: an enzymatic A subunit and a B subunit involved in the delivery of the A subunit into the target cell (Figure [1](#F1){ref-type="fig"}). The A subunit is an N-terminal glucosyltransferase domain (GTD) that inactivates host GTPases by glucosylation. Three additional domains within the B component are responsible for delivery of the GTD to the cytosol of the host cell. These include a receptor-binding domain, a "delivery" or pore-forming domain, and an autoprotease domain. The mechanism of action can be divided into four steps that are mediated by the four known domains: (1) binding/internalization, (2) pore-formation and translocation of the GTD across the membrane, (3) release of the GTD by autoproteolysis, and (4) inactivation of host GTPases by glucosylation (Figure [1B](#F1){ref-type="fig"}). The four main steps of intoxication are discussed below.

![**TcdA and TcdB primary structure and mechanism of cellular intoxication. (A)** TcdA and TcdB are homologous AB toxins consisting of four domains. The enzymatic A component is an N-terminal glucosyltransferase domain (GTD) (red). The B component, involved in delivery of the GTD into the cell, has three identified domains: combined repetitive oligopeptides (CROPs) (green), "delivery" or pore-forming (yellow), and autoprotease domains (blue). The orange box represents the hydrophobic region of the delivery domain that has been proposed to form part of the transmembrane pore (amino acids 956--1128 of TcdB). **(B)** The delivery process is divided into four main steps that are mediated by each of the four domains. (1) The toxin binds to the surface of the cell and is internalized by receptor-mediated endocytosis. (2) Acidification of the endosome triggers the formation of a pore through which the GTD is translocated. (3) The GTD is released into the cytosol by InsP6 dependent autoproteolysis. (4) The GTD glucosylates Rho family GTPases at the cell membrane.](fcimb-02-00028-g0001){#F1}

Receptor-binding
----------------

The C-termini of TcdA and TcdB consist of highly repetitive structures termed combined repetitive oligopeptides (CROPs) which are contained within amino acids 1832--2710 and 1834--2366, respectively (von Eichel-Streiber and Sauerborn, [@B119]; Ho et al., [@B41]). The CROPs are made up of multiple 19--24 amino acid short repeats (SRs) and 31 amino acid long repeats (LRs) (von Eichel-Streiber and Sauerborn, [@B119]; Jank et al., [@B45]). The TcdA CROPs domain comprises 32 SRs and 7 interspersed LRs (Figure [2A](#F2){ref-type="fig"}). The domain in TcdB is considerably shorter and contains 19 SRs and 4 LRs. Together the LR and SRs form cell wall binding motifs that bind sugar moieties on the surface of host cells (von Eichel-Streiber et al., [@B117],[@B120]). Cell wall binding motifs from TcdA were initially shown to bind α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc (Krivan et al., [@B55]). However, this sugar is not present on human cells (Tucker and Wilkins, [@B115]). TcdA has since been reported to bind to the human I, X, and Y blood antigens as well as a human glycosphingolipid which all have a core β-Gal-(1,4)-β-GlcNAc structure (Tucker and Wilkins, [@B115]; Teneberg et al., [@B112]). It is not known which of these, if any, serve as the native ligand in the human colon.

![**Structure of the CROPs domain.(A)** The TcdA CROPs domain is made up of 32 short repeats (SRs) with seven interspersed long repeats (LRs), which are represented by green and blue boxes, respectively. The TcdB CROPs domain consists of 19 SRs and 4 LRs. **(B)** Models of the TcdA and TcdB C-terminal repeats were constructed based on the structure of TcdA CROPs f1 (Ho et al., [@B41]). The models are colored as in **(A)**. **(C)** Carbohydrate recognition by the TcdA CROPs. The crystal structure of TcdA CROPs f2 (amino acids 2456--2710) is shown with the SRs colored green and LRs colored blue. The head-group of the bound liposaccharide α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAcO(CH~2~)~8~CO~2~CH~3~ is shown in yellow. **(D,E)** A close-up view of the trisaccharide-binding pocket formed by an LR and adjacent SR. The electrostatic surface potential is shown with negatively charged surfaces in red and positively charged surfaces in blue \[transparent in **(D)** and opaque in **(E)**\]. In **(D)** residues that make up the trisaccharide binding pocket are shown as sticks, and hydrogen bonds are shown as dashed lines. The labeled residues are strictly conserved in the saccharide-binding repeats of TcdA but are divergent in TcdB.](fcimb-02-00028-g0002){#F2}

Two proteins have been implicated as receptors for TcdA. Rabbit sucrose-isomaltase was first shown to serve as a receptor for TcdA in the rabbit ileum (Pothoulakis et al., [@B82]). Binding to sucrose-isomaltase was inhibited by galactosidase treatment, indicating that the toxin binds glycosyl modification(s) on the protein, but the identity of the sugar(s) is unknown (Pothoulakis et al., [@B82]). Rabbit sucrose-isomaltase cannot be the only receptor for TcdA, because many cells and tissues, including the human colonic epithelium, do not express this protein yet are sensitive to TcdA (Pothoulakis et al., [@B82]). More recently, human gp96 has been reported as a receptor for TcdA (Na et al., [@B73]). Like sucrose-isomaltase, gp96 is predicted to be glycosylated, but the identities of the saccharides have not been determined. It has not been shown for gp96 whether or not the saccharide modifications are involved in binding TcdA. No receptors have been described for TcdB.

In 2005, Ho et al. published the crystal structure of a fragment of TcdA comprising amino acids 2573--2709 (TcdA CROPs f1) \[pdb 2F6E (Ho et al., [@B41])\]. This fragment contains 4 SRs and 1 LR. The structure revealed that each repeating element consists of a β-hairpin followed by a loop. In the SRs, the loops are 7--10 amino acids in length, whereas the LR loop contains 18 amino acids. The SRs are packed together in a regular fashion where each repeat is rotated by ∼120° in relation to the previous one (Ho et al., [@B41]). The repetitive stacking of SRs forms straight, rod-like structures. The LR\'s packing with its adjacent SRs disrupts the regular repeating arrangement of the SRs, causing a ∼30° kink in the rod-like structure (Ho et al., [@B41]). Using the structure of the TcdA CROPs f1 as a template of SR-SR and SR-LR interactions, Ho et al. constructed a model of the entire TcdA and TcdB CROPs domains (Figure [2B](#F2){ref-type="fig"}).

The same group later published a co-crystal structure of a larger fragment (f2) of the TcdA C-terminal repeats in complex with an α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc derivative \[pdb 2G7C (Greco et al., [@B37])\]. This structure revealed that the saccharides bind at the junctions formed between LRs and SRs (Figure [2C](#F2){ref-type="fig"}). Thus, each of the kinked regions in Figure [2B](#F2){ref-type="fig"} represents a putative saccharide binding side. TcdA has 7 such binding sites, whereas TcdB has 4. The model taken from these structures implies multivalent binding along an extended binding domain (Greco et al., [@B37]).

The binding of α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc is shown in Figures [2C,E](#F2){ref-type="fig"}. The terminal α-Gal abuts the large loop of the LR and makes several hydrogen-bonding contacts with residues of the loop (e.g., Gln2638) (Figure [2D](#F2){ref-type="fig"}). The central β-Gal moiety sits with its methoxy group pointed down into a small acidic cleft formed in part by Glu2623. The oxygen of the methoxy group hydrogen bonds with Lys2661 of the SR. The GlcNAc group interacts with a number of SR residues including a hydrogen bond formed with Ser2660. The residues pointed out here (Glu2623, Gln2638, and Ser2660, Lys2661) are all strictly conserved in the saccharide binding repeats of the TcdA CROPs. Yet, these residues are strikingly different in the TcdB CROPs. Glu2623, for example, which contributes to the small acidic pocket where the β-Gal binds is replaced by a bulky, basic residue (lysine) in each of the TcdB LRs. Thus, while the TcdB CROPs are predicted to have a similar fold to the TcdA CROPs, the residues comprising the TcdA-saccharide binding sites are radically different. This provides a likely explanation for why TcdB does not bind the β-Gal-(1,4)-β-GlcNAc with the affinity of TcdA.

In addition to differences between TcdA and TcdB, it is also of note that the C-terminal repeats of TcdB from the prototypical 630 strain and TcdB from the hypervirulent R20291 strain differ considerably. The CROPs from the two toxins are 88% identical, with some of the individual repeats having less than 80% identity (Lanis et al., [@B59]). Interestingly, the TcdB variant from the TcdA^−^TcdB^+^ strain 8864 has CROPs similar to the R20291 TcdB (97% identical); whereas, the variant from the TcdA^−^TcdB^+^ strain 1470 resembles the prototypical strain (99% identical). Most of the differences in sequence are in the SRs, and the putative saccharide binding sites are largely conserved. It will be of interest to investigate if and how these amino acid changes impact cell binding.

There are a number of pieces of evidence that suggest that the CROPs are not the only parts of the proteins involved in binding to cells. The homologous toxin TpeL from *C. perfringens* lacks the C-terminal repeats yet is still toxic, albeit much less potent than its homologs (Table [1](#T1){ref-type="table"}) (Amimoto et al., [@B6]). Moreover, it has been shown that removing the CROPS from TcdA or TcdB attenuates but does not eliminate cytopathicity suggesting the existence of an additional binding activity outside carbohydrate-binding repeats (Barroso et al., [@B10]; Genisyuerek et al., [@B28]; Olling et al., [@B77]). This has been most thoroughly demonstrated for TcdA. TcdA lacking amino acids 1875--2710, which contains two SRs and no LRs (therefore, no saccharide binding sites), is able to intoxicate HT29 and 3T3 with 5--10-fold less potency than full-length toxin (Olling et al., [@B77]).

The additional binding activity may be encoded in the region preceding the C-terminal repeats. While removal of the CROPs of TcdB only partially reduces cytopathic potency, truncation to 1--1500 or 1--1529 completely attenuates cytopathicity (Barroso et al., [@B10]; Genisyuerek et al., [@B28]). If the receptor-binding domain from diphtheria toxin is attached to the truncated TcdB 1--1500, it regains its ability to intoxicate cells (Genisyuerek et al., [@B28]).

Pore formation
--------------

TcdA and TcdB enter the cell by clathrin-mediated endocytosis (Papatheodorou et al., [@B78]). Once the toxins have been internalized, the glucosyltransferase must be delivered across the endosomal membrane. Endosomal acidification is thought to induce structural changes in the delivery domain that expose hydrophobic segments. These hydrophobic regions insert into the host membrane forming a pore through which the glucosyltransferase domain can pass. This model, which was initially based on analogy to other pore-forming AB toxins, is now supported by several studies.

Qa\'Dan et al. have shown that acidification causes structural rearrangements in TcdB. The authors demonstrated that upon reduction of pH to 4.0, TcdB exhibits differences in native tryptophan fluorescence, protease susceptibility, and results in the exposure of hydrophobic surfaces (Qa\'Dan et al., [@B90]). Barth et al. demonstrated that acidification, not only induces conformational changes, but also triggers pore formation. Chinese hamster ovary (CHO) cells were preloaded with ^86^Rb^+^, and then treated with TcdB. Under acidic conditions, ^86^Rb^+^ was released into supernatant when TcdB was present, indicating that TcdB inserts into the plasma membrane and forms ion channels. The authors showed that TcdB can induce ion channels in artificial lipid bilayers at low pH (Barth et al., [@B11]). Barth et al. and Qa\'Dan et al. demonstrated that these results are also applicable in the natural intoxication of cells. Treatment of cells with pharmacological inhibitors of endosomal acidification (e.g., bafilomycin A1) retards the toxic effects of TcdB, presumably by inhibiting pore formation (Qa\'Dan et al., [@B90]; Barth et al., [@B11]).

Most studies on the pore-forming activity of the *C. difficile* toxins have used TcdB from strain 630. TcdA has also been shown to form channels in cells and in artificial bilayers (Giesemann et al., [@B34]). However, TcdA requires cholesterol for pore-formation whereas TcdB does not. TcdB from the NAP1/027 strain R20291 has been shown to enter cells more quickly and undergo pH-dependent conformational change at a higher pH than TcdB from strain 630 (Lanis et al., [@B59]). The molecular bases for these differences are unknown.

Pore formation and translocation are thought to be mediated by the central delivery domain (∼aa 801--1831). BLAST analysis of the delivery domain reveals two distinct regions of homology (Pruitt et al., [@B86]). We have termed these two regions D1 (∼801--1400) and D2 (∼1401--1831). Within D1, amino acids ∼956--1128 are particularly hydrophobic and have been hypothesized to compose at least part of the transmembrane pore (von Eichel-Streiber and Sauerborn, [@B119]; von Eichel-Streiber et al., [@B117]). Genisyuerek et al. have recently constructed a series of TcdB truncations to delineate the region of the toxin responsible for pore-formation (Genisyuerek et al., [@B28]). Proteins containing residues 1--990 and 830--2366 (or 830--1025) are capable of forming membrane channels at low pH suggesting that the amino acids 830--990 contain the minimal pore-forming region (Genisyuerek et al., [@B28]).

Within this region, the authors identified two residues (Glu970 and Glu976) that are involved in pore-formation (Genisyuerek et al., [@B28]). When both residues are mutated to lysine, the toxin is reduced in its ability to form pores at low pH and in its cytopathic potency. These residues may be involved in the pH sensing mechanism. At low pH, these acidic residues might be neutralized by protonation, which could facilitate their insertion into the membrane. These residues are not strictly conserved among LCTs, but most of the toxins do have acidic residues at these positions. TcdA, for example, has aspartate residues Asp972 and Asp978 which could play a similar role. The variant TcdB from strain 8864 is an exception; the residue corresponding to Glu970 is a glycine. The pore-forming activity of this toxin has not been studied.

The finding that amino acids 830--990 contains the minimal pore-forming sequence raises the question of what roles the other 875 residues in the delivery domain play in intoxication. The C-terminal part of the delivery domain (D2) may have a role in binding to cells as suggested in the previous section. So far, very little is known about the structure of the delivery domains of TcdA or TcdB in either the soluble or membrane states. It is also not known whether the toxins must oligomerize in order to form a pore. Understanding the structural changes that allow TcdA or TcdB to go from being soluble proteins to membrane pores is an exciting structural problem important for understanding the function of these proteins.

Autoproteolysis
---------------

LCTs are made and secreted as single polypeptide chains. It was unknown for many years whether the toxin remained intact or if the A component (GTD) was released into the cell as is typical for other AB toxins. It was first shown in 2003 that TcdB is proteolytically processed and that only the N-terminal GTD is released into the cytosol (Pfeifer et al., [@B80]). The cleavage site was localized between Leu543 and Gly544, and it was revealed that cleavage was mediated by a component of the target cell cytosol (Rupnik et al., [@B97]). It was thought that this proteolytic event was mediated by a host protease (Rupnik et al., [@B97]).

When Reineke et al. tried to identify the host factor required for cleavage of TcdB, they found that the host factor was not a protein but an inositol-phosphate (Reineke et al., [@B93]). The most active of the inositol-phosphates was inositol hexakisphosphate (InsP6) (Reineke et al., [@B93]). When mixed with purified LCTs, InsP6 alone was enough to induce cleavage. Egerer et al. confirmed that cleavage was stimulated by InsP6 and showed that a cysteine protease domain (CPD) adjacent to the GTD is responsible for cleavage (Egerer et al., [@B23]).

The CPD was identified based on its homology to a CPD that had just been discovered in the RTX toxin from *Vibrio cholerae* (Sheahan et al., [@B104]). As in the LCTs, the *V. cholerae* RTX (VcRTx) toxin CPD facilitates the release of enzymatic moieties into the target cell, and it is also activated by InsP6 (Prochazkova and Satchell, [@B83]). Crystal structures of the VcRTx \[pdb 3EEB, 3FZY (Lupardus et al., [@B60]; Prochazkova et al., [@B84])\], TcdA \[pdb 3HO6 (Pruitt et al., [@B85])\], and TcdB \[pdb 3PEE (Puri et al., [@B88])\] CPDs have revealed that these domains share a similar structure and mechanism of InsP6-induced activation. The domains have a central β-sheet flanked by a number of α-helices (Figure [3](#F3){ref-type="fig"}). The CPDs from TcdA and TcdB are larger than that of VcRTx, containing extended helical regions, an inserted β-strand, and a C-terminal extension, but the core fold of the structures is conserved (Lupardus et al., [@B60]; Pruitt et al., [@B85]). Three conserved catalytic residues, cysteine, histidine, and aspartate, cluster on the edge of the β-sheet (shown as orange sticks in Figure [3](#F3){ref-type="fig"}). InsP6 is bound at a separate site on one face of the β-sheet in a basic, lysine-rich pocket (Figure [3](#F3){ref-type="fig"}). The InsP6 binding pocket is separated from the catalytic triad by a structure termed the β-flap (Figure [3](#F3){ref-type="fig"}, β-flap colored purple).

![**Structures of the VcRTX, TcdA, and TcdB CPDs.** The crystal structures of the CPDs are shown as ribbon diagrams. InsP6 and the catalytic residues are shown as sticks (red and orange, respectively). The β-flap, shown in purple, separates the InsP6 binding pocket from the catalytic site. The N-terminus (dark blue) wraps around the protein such that the N-terminal cleavage site is near the catalytic residues.](fcimb-02-00028-g0003){#F3}

The aspartate, histidine, and cysteine residues of the catalytic site have been shown to be essential in the auto-proteolytic processing of VcRTx (Sheahan et al., [@B104]), TcdA (Pruitt et al., [@B85]), and TcdB (Sheahan et al., [@B104]). However, they do not form a conventional catalytic triad arrangement wherein the histidine forms a hydrogen bond with the cysteine making the cysteine more nucleophilic. The cysteine and histidine residues are, instead, separated by a large cleft. Rather than acting to increase the nucleophilicity of the cysteine, His655 may be important for stabilizing the oxyanion intermediate or protonating the leaving group (Prochazkova et al., [@B84]; Pruitt et al., [@B85]).

The discovery of the CPD in TcdA and TcdB presents a potential new target for therapeutics inhibiting the toxins. Puri et al. have developed a number of small molecule inhibitors of TcdB that act by covalent modification of the catalytic cysteine (Puri et al., [@B88]). A crystal structure of the TcdB CPD was determined bound to one of these compounds, acyl-Gly-Ser-Leu-acyloxymethyl ketone (Ac-GSL-AOMK) (Figure [4](#F4){ref-type="fig"}) \[pdb 3PA8 (Puri et al., [@B88])\]. Ac-GSL-AOMK is a mimic of the native TcdB substrate (Gly-Ser-Leu↓Ser-Glu-Asp). The leucine side chain of the inhibitor binds in a hydrophobic pocket immediately adjacent to the catalytic site (Figure [4](#F4){ref-type="fig"}). The hydrophobic residues involved in binding to the substrate are largely conserved among LCTs and RTX CPDs, and all of these CPDs cleave after a leucine. The crystal structure of an inactive VcRTX CPD with the substrate bound reveals that this protease has a similar mechanism of substrate binding \[pdb 3FZY (Prochazkova et al., [@B84])\].

![**Inhibition of the TcdB by covalent modification of the active site.** The TcdB CPD catalytic site is shown with the substrate mimic acyl-Gly-Ser-Leu-acyloxymethyl ketone (Ac-GSL-AOMK) (green) bound. Catalytic residues are shown in orange and InsP6 is shown in red. The leucine side chain of the Ac-GSL-AOMK is bound in a hydrophobic substrate binding pocket (blue).](fcimb-02-00028-g0004){#F4}

The CPD structures were obtained in the presence of InsP6. NMR, circular dichroism, and limited proteolysis of the TcdA CPD suggests that the domain is folded in both apo- and InsP6-bound proteins but that InsP6 binding confers stability and induces significant structural change (Pruitt et al., [@B85]). Recent work by Shen et al. has demonstrated that the TcdB CPD exists in a dynamic equilibrium between active and inactive states (Shen et al., [@B107]). InsP6 binding shifts the equilibrium markedly toward the active conformation. Shen et al. show by mutational analysis that the β-flap plays an important role in the allosteric activation mechanism by coupling the InsP6-binding and catalytic sites.

Cleavage is not equivalent between TcdA and TcdB. TcdB holotoxin is more sensitive than TcdA holotoxin to InsP6-induced cleavage in *in vitro* reactions (Kreimeyer et al., [@B54]). The basis for this difference is not readily apparent from the structures of the CPD domains from the two toxins. It is possible that these differences in sensitivity to InsP6 are due to areas outside the domain. In our observations, the TcdA holotoxin undergoes processing much less efficiently than a small fragment containing the protease domain (510--809). Therefore, factors outside the protease domain affect cleavage, possibly to prevent premature processing.

Collectively, the aforementioned structural and biochemical data have revealed that InsP6-mediated autoproteolysis is a conserved mechanism used by diverse toxins to release their cargo into eukaryotic cells. This novel autoprocessing mechanism is reviewed in greater detail in (Shen, [@B105],[@B106]) and (Egerer and Satchell, [@B24]).

Glucosyltransfer
----------------

The N-termini of the LCTs contain a 63 kDa GTD which is released into the cell and inactivates small GTPases. GTPases are molecular switches that cycle between active GTP-bound and inactive GDP-bound states. Upon binding GTP, GTPases undergo a conformational change allowing them to interact with several effector molecules (Bishop and Hall, [@B13]; Aktories and Barbieri, [@B3]). The repertoire of effector molecules is extensive and includes protein and lipid kinases, phosphatases, lipases, and scaffolding proteins. The downstream signaling cascades induced by activation of Rho family GTPases are principally involved in the regulation of the cytoskeleton and processes requiring cytoskeletal rearrangements.

TcdA and TcdB preferentially act on GDP-bound, membrane associated Rho GTPases (Just et al., [@B48]; Genth et al., [@B29]). Using UDP-glucose as a co-substrate, the toxins inactivate Rho proteins by monoglucosylation of Thr37 (Thr35 of Rac and Cdc42) (Aktories and Just, [@B4]; Just et al., [@B48]). Thr37 is located in the switch I region which is important for binding effectors and regulatory proteins (Genth et al., [@B29]; Aktories and Barbieri, [@B3]; Jank et al., [@B45]). Glucosylated Rho GTPases are no longer able to interact with regulatory molecules or many of its effectors, and therefore, numerous downstream signaling pathways are interrupted (Herrmann et al., [@B39]; Sehr et al., [@B102]; Genth et al., [@B29]; Aktories and Barbieri, [@B3]; Jank et al., [@B45]).

Based on *in vitro* experiments, TcdA and TcdB can target RhoA, RhoB, RhoC, RhoG, Rac1, Cdc42, and TC10 (Jank et al., [@B45]; Genth et al., [@B30]). TcdA has been reported to modify the additional substrates Rap1A and Rap2A which are more closely related to Ras family proteins (Chaves-Olarte et al., [@B17]). TcsH and Tcnα also target Rho family substrates (Table [1](#T1){ref-type="table"}) (Genth et al., [@B31]; Selzer et al., [@B103]). TcsL and TpeL, on the other hand, act mostly on Ras family proteins such as H-Ras, Ral, and Rap (Nagahama et al., [@B74]). They can target Rac but not Rho. Like the Rho proteins, the Ras GTPases are involved in a large number of cellular signaling pathways. They have important roles in the regulation of cell-cell junctions, cell proliferation, and survival (Raaijmakers and Bos, [@B91]).

The TcdB variants produced by strains 1470, 8864, and C34 modify Ras family substrates (Chaves-Olarte et al., [@B16]; Mehlig et al., [@B69]; Huelsenbeck et al., [@B43]). These toxins are sometimes referred to as functional hybrids because most of the TcdB protein is the same as in prototypical strains, but the GTD modifies the same substrates as TcsL. Interestingly, all of the TcdA^−^TcdB^+^ strains that have been characterized so far carry these variant toxins. It is not known why some toxins preferentially target Rho family proteins while others target Ras family proteins, but it is clear that the inactivation of these different proteins has different effects on cells (Giry et al., [@B35]; Chaves-Olarte et al., [@B16]; Mehlig et al., [@B69]; Huelsenbeck et al., [@B43]). TcsL and variant TcdBs which modify Ras family proteins cause cells to have a spindle-like appearance (S-type cytopathic effect), whereas treatment with TcdA and prototypical TcdB results in an arborized appearance (D-type cytopathic effect) (Torres, [@B113]; von Eichel-Streiber et al., [@B118]; Mehlig et al., [@B69]).

In 2005, Reinert et al. determined the crystal structure of the TcdB GTD in complex with UDP-glucose \[pdb 2BVM (Reinert et al., [@B94])\]. The structures of the GTDs from three other LCTs, TcdA, TcsL, and Tcnα, have also been determined \[pdb 3SS1/3SRZ (Pruitt et al., [@B87]), 2VKD/2VKH, and 2VK9 (Ziegler et al., [@B125])\]. These structures coupled with biochemical data have shed light on the enzymatic mechanism of glucosyltransfer. The structure of the TcdB GTD is presented in Figure [5](#F5){ref-type="fig"}. At the core of the structure is a Rossman fold similar to what is seen in other glycosyltransferases belonging to the glycosyltransferase A (GT-A) family (Reinert et al., [@B94]). In addition to the common GT-A family fold, TcdB has a number of α-helical additions (red). These include an N-terminal 90-residue subdomain at the "bottom" of the GTD, as presented in Figure [5A](#F5){ref-type="fig"}, and several other large protuberances at the "top right" and "top left." The N-terminal subdomain has recently been shown to target the GTD to the plasma membrane, the site of the target GTPases (Mesmin et al., [@B71]; Geissler et al., [@B27]). This region is, therefore, referred to as the membrane localization domain (MLD). The role of the other α-helical additions is unknown, but it has been suggested that these residues are involved in substrate binding (Reinert et al., [@B94]).

![**Structure of the TcdB glucosyltransferase domain. (A)** The core GT-A fold is shown in orange, and the α-helical additions are shown in red. The N-terminal four-helix bundle makes up the MLD. **(B)** Close up view of the catalytic core. UDP, glucose, and a manganese ion are bound on the surface of the core GT-A fold. The binding pocket is overlayed by a loop comprising residues 517--523. Some of the residues involved in coordinating UDP, Glucose, and Mn^2+^ are shown as sticks. **(C)** Surface view of the TcdB GTD as shown in **(A)**. Glu449, Arg455, Asp461, Lys463, and Glu472, residues that have been shown to be involved in GTPase binding, are colored cyan.](fcimb-02-00028-g0005){#F5}

The structure of the TcdB GTD facilitated the identification of important residues in the reaction mechanism. The α-anomeric conformation of the glucose is retained in the glucosyltransfer reaction (Vetter et al., [@B116]), and is thus thought to proceed through a carboxonium intermediate (Ziegler et al., [@B125]). In the TcdB GTD structure, UDP-glucose is hydrolyzed into UDP and glucose, but both molecules are bound along with the cofactor Mn^2+^ (Ciesla and Bobak, [@B19]; Reinert et al., [@B94]). As in other GT-A proteins, UDP-glucose is bound in a pocket formed by the edge of the β-sheet and several α-helices. A loop consisting of residues 517--523 overlays the binding pocket, and two residues within this loop (Ser518 and Trp520) are involved in binding the phosphate group of UDP (Figure [5B](#F5){ref-type="fig"}). Figure [5B](#F5){ref-type="fig"} shows several other key residues that are involved in binding UDP-glucose. The activity of the enzyme is reduced or abolished when any of these residues are mutated (Hofmann et al., [@B42]; Jank et al., [@B44]).

The structure of the TcdB GTD was used as a platform to discover residues that are involved in binding target GTPases. Jank et al. have found 5 residues (Glu449, Arg455, Asp461, Lys463, and Glu472) that when mutated result in loss of substrate modification. These residues are located adjacent to the UDP-glucose binding pocket (cyan in Figure [5C](#F5){ref-type="fig"}). The transferred glucose is only accessible from this "front" view of the GTD, thus the GTPases must bind to this side of the molecule.

Our lab has recently determined the structure of the TcdA GTD (Pruitt et al., [@B87]). The overall fold and UDP-glucose binding core of the TcdA and TcdB GTDs are similar, but the surfaces of the two domains are very different (Figure [6](#F6){ref-type="fig"}). These differences are particularly striking on the proposed GTPase binding surface. Differences on this surface are likely responsible for differential substrate specificities. Notably, the residues which have been shown to be involved in binding of TcdB to substrates (Figure [5C](#F5){ref-type="fig"}, cyan) are not conserved among the LCTs. This is also evident when examining TcdB from different strains. TcdB from the prototypical strain 630 and the NAP1/027 R20291 have conserved residues on the substrate binding surfaces. Isoforms from the TcdA^−^TcdB^+^ strains 8864 and 1470, as well as TcdB from strain C34, have accumulated a large number of mutations on the substrate-binding surface relative to the TcdB from strain 630 (Figure [7](#F7){ref-type="fig"}) (Reinert et al., [@B94]). In 1470, 8864, and C34 TcdB the toxins have altered substrate recognition, targeting Ras GTPases in addition to Rho family proteins. These GTD variants are typically found in strains lacking TcdA, and may have arisen to compensate for the loss of TcdA, which can modify at least a subset of Ras family proteins (Rap2A).

![**The GTPase binding surfaces of the LCTs are diverse.** The electrostatic surface potentials of the GTDs of TcdA, TcdB, TcsL, and Tcnα are shown with basic surfaces in blue and acidic surfaces in red. These varied surfaces likely influence substrate binding specificity. The *in vitro* substrates are listed below each GTD.](fcimb-02-00028-g0006){#F6}

![**Variation of the substrate binding surface of TcdB from different strains.** Sequences of TcdB from strains 630, R20291, 1470, 8864, and C34 were aligned. The homology score for each residue was mapped onto the surface of the TcdB GTD using ESPript and PyMOL (Gouet et al., [@B36]). Strictly conserved residues are shown in red; divergent residues are shown in blue.](fcimb-02-00028-g0007){#F7}

Holotoxin structure
-------------------

The structures of the individual domains of TcdA and TcdB have provided considerable insight into the processes of receptor-binding, autoprocessing, and enzymatic inactivation of host GTPases. A structure of the delivery domain would be of considerable interest, as pore-formation and translocation of the GTD are poorly understood steps of the toxin mechanism. However, a complete understanding of toxin function will require an understanding of how these domains interact with each other in the context of the holotoxin. Low resolution maps of the holotoxins have been determined by small angle X-ray scattering (SAXS) and negative stain electron microscopy (EM). The SAXS study was carried out on TcdB and revealed a modular structure into which a structure of the TcdB GTD and models of the CPD and CROPs domain could be placed (Albesa-Jove et al., [@B5]).

We have used negative stain EM to determine a 25 Å resolution structure of TcdA (Pruitt et al., [@B86]). The EM structure reveals a bi-lobed structure from which there are two protrusions, one long, and curved and the other shorter and wider. Within this map we were able to experimentally localize three of the four domains (Figure [8](#F8){ref-type="fig"}). The bi-lobed structure comprises the delivery domain. These two lobes may make up the two delivery subdomains, D1 and D2. The shorter of the protrusions represents the GTD, and the long curved protrusion corresponds to the C-terminal repeats, and is consistent with the model of the CROPs domain proposed by Ho et al. ([@B41]).

![**Domain organization of TcdA at neutral and low pH.** EM structures are colored by functional domain. GTD, red; CPD, blue; delivery domain, yellow; CROPs, green. The dashed line represents possible unfolding of the TcdA GTD N-terminus at low pH.](fcimb-02-00028-g0008){#F8}

The structure of TcdA described above represents a single state of the protein. However, these toxins undergo a number of conformational changes in response to environmental signals during cellular intoxication. To begin investigating changes that the toxin must undergo to insert into the membrane and form a pore, we have also determined a structure of TcdA on the EM grid following exposure to low pH (Pruitt et al., [@B86]). Upon exposure to low pH, there are major changes within the delivery and glucosyltransferase domains (Figure [8](#F8){ref-type="fig"}). The delivery domain takes on a more elongated shape as opposed to the bi-lobed structure. This may reflect a change necessary for exposure of hydrophobic residues that would insert into the membrane. There is also a notable loss of density for the GTD. We suggest that this is due to an unfolding of the GTD at low pH, which would facilitate its translocation through the pore.

These structures have provided and initial map of the organization of the holotoxin. They are limited however, by their low resolution. A combination of structural approaches will likely be necessary to refine this model and understand the structural changes that the toxins must undergo to accomplish the complex task of cargo delivery.

Questions for future study
==========================

As the primary virulence factors of *C. difficile*, TcdA and TcdB are prime therapeutic targets for treatment of CDAD. Still, many questions remain regarding how the toxins deliver their cytopathic cargo into target cells. What are the receptors for TcdA and TcdB, and what cells do they target *in vivo*? Does D2 have a role in binding to host cells? What is the nature of the pore structure of the toxins? What structural rearrangements are necessary for the toxins to access this pore state? How is the GTD translocated through this pore? How is the autoprotease activity occluded in the holotoxin, and when/how does it become activated?

There is also much to be learned about substrate modification in cells. It is not clear how the GTDs bind their substrates and how the distinct surfaces drive specificity for the target GTPases. Most of what we know about toxin substrate specificity is from *in vitro* experiments. Membrane localization and host factors likely play an important role in determining what substrates are modified *in vivo*, so the array of actual targets may be different. Finally, the consequences of modifying different subsets of GTPases for pathogenesis are not known. Clearly, a great deal of work needs to be done to understand the action of these toxins. Elucidating the answers to these questions will help uncover the different roles of TcdA, TcdB, and variant toxins and aid in the development of strategies to prevent their action.
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